Shankar Musunuri - Nov 1, 2021 Form 4 Insider Report for Ocugen, Inc. (OCGN)

Role
Chief Executive Officer, Director
Signature
/s/ Shankar Musunuri by Sanjay Subramanian, his attorney-in-fact
Stock symbol
OCGN
Transactions as of
Nov 1, 2021
Transactions value $
-$1,573,606
Form type
4
Date filed
11/3/2021, 07:38 PM
Previous filing
Oct 15, 2021
Next filing
Nov 18, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCGN Common Stock Options Exercise $58.8K +115K +28.42% $0.51 521K Nov 1, 2021 Direct
transaction OCGN Common Stock Sale -$1.63M -115K -22.13% $14.15 406K Nov 1, 2021 Direct F1, F2
holding OCGN Common Stock 1.38M Nov 1, 2021 By: KVM Holdings, LLC F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCGN Option (Right to Buy) Options Exercise $0 -115K -15.64% $0.00 622K Nov 1, 2021 Common Stock 115K $0.51 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.07 to $14.33. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The Reporting Person is a member and officer of KVM Holdings, LLC and has voting and investment power over the shares held by KVM Holdings, LLC.
F4 The option, initially representing a right to purchase a total of 933,528 shares, vests and becomes exercisable annually in equal installments over three years commencing on January 2, 2021, subject to continued employment with the Company on the applicable vesting dates.